{
    "ticker": "KRBP",
    "name": "Karuna Therapeutics, Inc.",
    "description": "Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neuropsychiatric diseases. Founded in 2016, Karuna's mission is to transform the treatment landscape for patients suffering from schizophrenia and other debilitating mental health disorders. The company is focused on advancing its lead candidate, KarXT, an investigational drug designed to harness the potential of the brain's natural signaling pathways to address the unmet needs of patients with schizophrenia. Karuna's approach is grounded in a deep understanding of the mechanisms of action of psychedelics and antipsychotics, aiming to provide a superior therapeutic profile with improved efficacy and tolerability. The company is committed to rigorous clinical research and has received fast track designation from the FDA for KarXT, reflecting its potential to offer significant advancements in treatment options. Karuna Therapeutics is also exploring additional indications and therapeutic areas in the mental health space, underscoring its dedication to improving patient outcomes and quality of life. With a strong scientific foundation and a team of experienced professionals, Karuna is poised to make meaningful contributions to the field of psychiatry and neurology.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Boston, Massachusetts, USA",
    "founded": "2016",
    "website": "https://www.karunatx.com",
    "ceo": "Andrew E. D. Miller",
    "social_media": {
        "twitter": "https://twitter.com/KarunaTx",
        "linkedin": "https://www.linkedin.com/company/karuna-therapeutics/"
    },
    "investor_relations": "https://ir.karunatx.com",
    "key_executives": [
        {
            "name": "Andrew E. D. Miller",
            "position": "CEO"
        },
        {
            "name": "David S. Morrow",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Clinical Development",
            "products": [
                "KarXT"
            ]
        }
    ],
    "seo": {
        "meta_title": "Karuna Therapeutics, Inc. | Innovative Neuropsychiatric Treatments",
        "meta_description": "Explore Karuna Therapeutics, Inc., a leader in developing novel therapies for neuropsychiatric diseases. Learn about KarXT and the company's commitment to patient health.",
        "keywords": [
            "Karuna",
            "Neuropsychiatry",
            "Schizophrenia Treatment",
            "Biotechnology",
            "Clinical Trials"
        ]
    },
    "faq": [
        {
            "question": "What is Karuna Therapeutics known for?",
            "answer": "Karuna Therapeutics is known for developing innovative treatments for neuropsychiatric diseases, particularly schizophrenia."
        },
        {
            "question": "Who is the CEO of Karuna Therapeutics?",
            "answer": "Andrew E. D. Miller is the CEO of Karuna Therapeutics, Inc."
        },
        {
            "question": "Where is Karuna Therapeutics headquartered?",
            "answer": "Karuna Therapeutics is headquartered in Boston, Massachusetts, USA."
        },
        {
            "question": "What is KarXT?",
            "answer": "KarXT is an investigational drug being developed by Karuna Therapeutics for the treatment of schizophrenia."
        },
        {
            "question": "When was Karuna Therapeutics founded?",
            "answer": "Karuna Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "ALNY",
        "PTGX",
        "SAGE"
    ],
    "related_stocks": [
        "BIIB",
        "GILD",
        "VRTX",
        "REGN"
    ]
}